Loading viewer...
earnings
Format: PDF earnings
Hansa Biopharma's year-end 2022 conference presentation reports total revenue of SEK 155m and Idefirix product launch progress across Europe with market access secured in 11 countries. The company highlights positive clinical trial data in antibody-mediated rejection and advances in its imlifidase pipeline across multiple indications including anti-GBM, GBS, and DMD-related studies. With $40 million raised in a direct share issue, Hansa extended its cash runway into 2025 and progressed toward planned BLA submission in 2024.
conference
17 Pages
Hansa Biopharma Investor Presentation — April 2024
investor_presentationinvestor_presentation
99 Pages
earnings
24 Pages
Alfa Laval
PayPal Q1 2023 Investor Update – Earnings
earningsearnings
33 Pages
PayPal Holdings, Inc.
Diversified Energy Q2 2024 Interim Results August
earningsearnings
15 Pages
Diversified Energy Company
Micron Technology Q3 2016 Earnings Results
earningsearnings
26 Pages
Micron Technology, Inc.